Covington Advises Silence Therapeutics Plc on Equity Fundraising

Covington Advises Silence Therapeutics Plc on Equity Fundraising

May 2, 2013

LONDON, 2 May, 2013 — Silence Therapeutics Plc, a leader in the discovery, development and delivery of novel RNA interference therapeutics for the treatment of serious diseases, has successfully raised £18.7 million of new funds. Covington & Burling advised Silence Therapeutics on the transaction.

The Company expects to use the net proceeds of the placing of £18.7 million to fund a Phase Ib/IIa programme of Atu027, its most advanced internal drug candidate for the treatment of solid tumours, as well as to develop its non-cancer projects and broaden its clinical expertise.

The London-based Covington team was led by corporate partner Natalie Walter with assistance from corporate associate Simon Williams.